Sultan Çalışkan

GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors

Özgür Mete, Mehmet Kefeli, Sultan Çalışkan et al. · Modern Pathology · 2018 · 74 citations · Full text

Neuro-oncology, Tumor Biology, Radiation Oncology +12

Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas

Hasan Güçer, Sultan Çalışkan, Mehmet Kefeli et al. · Endocrine Pathology · 2020 · 33 citations

Your Pax8 Antibody, Medicine, Medullary Thyroid Carcinomas +7

Leiomyoma With Bizarre Nuclei: Clinical and Pathologic Features of 30 Patients

Mehmet Kefeli, Sultan Çalışkan, Emel Kurtoğlu et al. · International Journal of Gynecological Pathology · 2017 · 25 citations

Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study

Elif Tutku Durmuş, Ayşegül Atmaca, Mehmet Kefeli et al. · Growth Hormone & IGF Research · 2022 · 20 citations

Tumor Subtype, Growth Hormone, Analogue Therapy +10

Pd-l1 expression in medullary thyroid carcinoma and its association with clinicopathological findings

Yasemi̇n Kemal, Sultan Çalışkan, Seda Gün et al. · Turkish Journal of Pathology · 2021 · 10 citations · Full text